AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug

Health insurer Highmark inked an outcomes-based contract with AstraZeneca (NYSE:AZN) for Symbicort, the pharmaceutical company’s drug designed to treat asthma and chronic obstructive pulmonary disease.

Highmark said its contract with AstraZeneca is one of the first outcomes-based deals involving a respiratory drug and will apply to commercial members of its national and core markets in Pennsylvania, West Virginia and Delaware.

Get the full story at our sister site, Drug Delivery Business News.

The post AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug appeared first on MassDevice.

Rani Therapeutics nabs $53m for robotic pill injection tech

  • Steve Maxson joins Fermatex as VP of marketing and sales

    Fermatex Vascular Technologies (formerly Gore-Jersey Shore and Adam Spence Corporation) recently announced that Steve Maxson has joined the company as VP of marketing and sales. “I’m very pleased to have Steve join the Fermatex team at this exciting time of transition and growth. His technical experience and commitment to responsive service will ensure that we remain […]

  • Nearly 90% of clinicians will use bedside mobile tech by 2022, study says

    A new study from Zebra Technologies reports that 9 out of 10 clinicians will use mobile technology at the bedside for acute care within the next four years. The company received feedback from 1,500 nursing managers, IT decision-makers and patients to determine how patient care will transform by 2022. The ability to use mobile devices […]

  • Trumpf touts newest laser technology at Photonics West

    Trumpf is touting its TruMicro 5370 and TruMicro 7380, Dira 200-5 and a TruLaser Station 5005 with a TruMicro 2030 laser system Photonics West in San Francisco, Calif. at booth #817. The company’s short and ultra-short pulsed TruMicro 5370 and 7380 lasers are designed for micro-processing. They are used in standard processing methods like cutting, drilling, […]

  • Dow touts versatility in latest LSR grades for overmolding

    Dow Medical Solutions, a business unit of the DowDuPont Specialty Products Division has introduced two new liquid silicone rubber (LSR) technologies to support a broader range of rigid plastic substrates for overmolding applications. These new elastomeric products give designers and manufacturers greater options for creating differentiated devices with improved safety and durability. The two grades include […]

  • Spectralytics launches DFM product development facility for laser services

    In the new medtech manufacturing environment, design engineers need parts faster, with fewer iterations and quicker turnaround. Spectralytics aims to meet those needs with its revamped development center in Maple Plain, Minn. The laser cutting and processing contract manufacturer has a newly expanded facility dedicated to design and prototyping. The 15,000 sq. ft. facility is located […]

  • Mack Molding systematizes ISO 9001 and 13485 revisions

    Mack Molding recently announced that is has started the process of systematizing ISO 9001:2015 and ISO 13485:2016 fifth and third revisions for medical devices. The company plans to train internal auditors to help assure that Mack Molding is ready to be certified after audits that are scheduled for July. “When we first implemented ISO 9001 […]

  • GW Plastics expands in-house tooling capabilities

    GW Plastics (Royalton, Vt.) recently announced that it has expanded and upgraded its tooling facility, adding additive manufacturing technology. The company has invested in medical 3D printing technology to help with conformal cooling and improve cycle times up to 30%. “This additive manufacturing technology streamlines tool design, reducing the components needed to build a mold […]

  • Raumedic investing in modernizing headquarters

    Raumedic (Helmbrechts, Germany) is investing 1 million Euros in expanding and modernizing its German headquarters. The company will add a state-of-the-art customer center while improving working conditions for employees. The company is adding a new foyer with additional meeting areas. The older buildings at the Helmbrechts-based headquarters will be the main areas undergoing modernization, which […]

  • Software is a top cause of medical device recalls: Here’s what you can do

    Stericycle Expert Solutions recently conducted a five-year assessment of recall trends, based on its quarterly Recall Index studies. The results show surprising missteps from medical device companies, especially where software is concerned. We asked Chris Harvey, director of recall solutions at Stericycle to answer some questions about the recall trends and offer some advice on […]

  • Report: Medical device recalls down in Q4 of 2017

    The medical device industry saw a 9% decline in recalls in the last quarter of 2017, the lowest quarter since the fourth quarter of 2011. Stericycle Expert Solutions reports in its annual Recall Index that one of the major causes of medical device recalls over the past five years is technological advances. Chris Harvey, director […]

  • Webinar: How a 3D printer’s versatility enables medical innovation

    Wednesday, Feb. 21, 2018 11:30am Eastern time / 8:30am Pacific time     View this webinar to learn how 3D printing’s versatility has paved the way for medical advancements by Cardiovascuar Systems. To help fight the battle against CAD and PAD, CSI works continuously to advance their devices and develop new innovations – work that […]

  • Adherium to expand in U.S. market with direct-to-consumer push for smart inhaler tech

  • Medical device startups: Here’s how you handle requirements

    Developing the product requirements is one of the most complex activities associated with product development, yet one of the most important.  Bill Betten, Betten Systems Solutions This is the third in a series of articles that discusses the design of innovative products in the highly regulated medical environment. The previous two articles focused on the […]

  • How does autonomous robotic surgery affect product liability?

    As more medical device manufacturers offer autonomous robotic surgery to their surgeon customers, traditional lines of legal defense most often taken by companies may change, according to experts from Nutter. David L. Ferrera and Melanie V. Woodward, Nutter Robots in surgery are not new. Indeed robots have been assisting surgeons for years, giving surgeons more […]

  • Medtech stories we missed this week: Jan. 26, 2018

    From Attune Medical receiving FDA 510(k) clearance to Synapse Medical having CE Mark approval, here are some medtech stories we missed this week but thought were still worth mentioning. 1. Attune Medical gets FDA 510(k) clearance Attune Medical announced in a Jan. 8 press releasethat it has received FDA 510(k) clearance for its EnsoETM model […]

  • The 5 biggest issues in patenting combo products

    Complexity and ownership issues make combination products a patenting labyrinth. Here are five key points to help you navigate the maze. David J. Dykeman and Roman Fayerberg, Greenberg Traurig The rise of personalized medicine has spurred another trend: the growth of combination products that blend biologics, drugs and medical devices to improve patient treatment. However, […]

  • FDA, FTC warn companies over deceptive opioid cessation products

    The FDA and the Federal Trade Commission have posted joint warning letters to companies that make and distribute opioid cessation products. The two watchdogs warned that the companies are illegally marketing their unapproved products as treatments or even cures for people with opioid addiction and withdrawal. Selling unapproved products as therapies for opioid addiction is […]

  • Why customer-centric marketing isn’t enough for medtech

    Customer-centric marketing has been a key pillar of marketing strategies across industries in recent years. But in medtech, the marketing ecosystem is a little more complicated. Rachel Mele, Vennli Customer-centricity has been a key pillar of marketing strategies across industries in recent years. In 2016, nine in 10 CMOs said their organizations were trying to become […]

  • How FDA’s digital health plan is shaking up its review process

    FDA is asking questions about how to overhaul digital health product regulation and relying on expertise within the industry to do so, according to Bakul Patel, FDA’s associate center director for digital health, who recently spoke with MDO. In late 2017, FDA launched the Digital Health Innovation Action Plan. Within that plan is a recipe […]

  • 3 secrets of medtech success from a true industry pioneer

    From stents to TAVR, Stanton Rowe has built a medtech legacy out of accomplishing the seemingly impossible. Here are three lessons from his career. Stanton Rowe has played a major role in two of the top medtech innovation success stories of recent decades: stents and transcatheter valve replacements. Listening to him speak at DeviceTalks West […]

  • Report: CMS nixes plans for pathway for expedited medical device coverage

    The Centers for Medicare & Medicaid Services has cancelled plans to create a new regulatory pathway that aimed to accelerate medicare coverage for medical devices, according to a ModernHealthcare report. The federal agency reportedly withdrew the proposition, known as Excite, from review at the White House’s Office of Management and Budget this month, nine months after […]

  • What should really trigger a CAPA?

    When should a problem with a medical device trigger a CAPA (Corrective Action and Preventative Action)? Jon Speer at Greenlight Guru has some thoughts.  Jon Speer, Greenlight Guru After years of working with medical device companies, we’ve found that there is a particular area that is often rife with issues for companies: CAPA (Corrective Action and Preventative Action). […]

  • 3M submits 510(k) for steam sterilization system

    3M has submitted an application to receive FDA 510(k) clearance for its Attest Super Rapid System for steam sterilization. The steam sterilization system can provide biological indicator results in 24 minutes. A faster readout time for steam will help improve patient safety while increasing workflow for sterilization professionals. “The focus of our sterilization science at […]

  • FDA clears AstraZeneca’s once-weekly Type II diabetes drug-device combo

    Share

    AstraZeneca BydureonAstraZeneca (NYSE:AZN) said today that the FDA approved its once-weekly exenatide drug in a single-dose auto-injector for adults with Type II diabetes whose blood sugar is uncontrolled on one or more oral drugs.

    The company’s drug, Bydureon, is formulated with a continuous-release microsphere delivery system designed to provide consistent levels of exenatide, according to AstraZeneca, to reduce blood sugar levels in people with diabetes.

    Get the full story at our sister site, Drug Delivery Business News.